Fig. 1: Clinical trial diagrams of Neo-T therapy. | Nature Communications

Fig. 1: Clinical trial diagrams of Neo-T therapy.

From: A pilot study of lymphodepletion intensity for peripheral blood mononuclear cell-derived neoantigen-specific CD8 + T cell therapy in patients with advanced solid tumors

Fig. 1: Clinical trial diagrams of Neo-T therapy.The alternative text for this image may have been generated using AI.

A Clinical trial flowchart. 24 patients were enrolled in this trial, and 11 patients received Neo-T therapy with different dose intensities of lymphodepletion. High dose group: both 500 mg/ m2 cyclophosphamide (CTX) and 25 mg/m2 fludarabine (FDR) for 2 days; Low dose group: 500 mg/m2 CTX for 1 day and 25 mg/m2 FDR for 2 days; and no lymphodepletion group. B Clinical trial scheme. Schematic depicting the phase I clinical trial. Nonmyeloablative lymphodepletion regimen was administered on days −5 and −4. Next, Neo-T cells were administered on Day 0. And 2 courses of Neo-T treatment were given to each patient, with 1 infusion/month and 3 infusions/course. CT (Computed Tomography) scan was conducted every two months after the first cell infusion.

Back to article page